KR20150001711A - 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 - Google Patents

생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 Download PDF

Info

Publication number
KR20150001711A
KR20150001711A KR20147010620A KR20147010620A KR20150001711A KR 20150001711 A KR20150001711 A KR 20150001711A KR 20147010620 A KR20147010620 A KR 20147010620A KR 20147010620 A KR20147010620 A KR 20147010620A KR 20150001711 A KR20150001711 A KR 20150001711A
Authority
KR
South Korea
Prior art keywords
cell
nanoparticles
nanoparticle
altering
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR20147010620A
Other languages
English (en)
Korean (ko)
Inventor
앤드라닉 앤드류 애프리키언
킬리언 딜
Original Assignee
스템제닉스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스템제닉스 인코포레이티드 filed Critical 스템제닉스 인코포레이티드
Publication of KR20150001711A publication Critical patent/KR20150001711A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/34—Belt retractors, e.g. reels
    • B60R22/341—Belt retractors, e.g. reels comprising energy-absorbing means
    • B60R22/3413—Belt retractors, e.g. reels comprising energy-absorbing means operating between belt reel and retractor frame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/286—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices using deformation of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60R—VEHICLES, VEHICLE FITTINGS, OR VEHICLE PARTS, NOT OTHERWISE PROVIDED FOR
    • B60R22/00—Safety belts or body harnesses in vehicles
    • B60R22/28—Safety belts or body harnesses in vehicles incorporating energy-absorbing devices
    • B60R2022/289—Energy-absorption curves
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
KR20147010620A 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자 Ceased KR20150001711A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550213P 2011-10-21 2011-10-21
US61/550,213 2011-10-21
PCT/US2012/061391 WO2013059831A1 (en) 2011-10-21 2012-10-22 Functionalized nanoparticles for intracellular delivery of biologically active molecules

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018256A Division KR20190077124A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자

Publications (1)

Publication Number Publication Date
KR20150001711A true KR20150001711A (ko) 2015-01-06

Family

ID=48141479

Family Applications (3)

Application Number Title Priority Date Filing Date
KR20147010620A Ceased KR20150001711A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
KR1020197018256A Ceased KR20190077124A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
KR1020207010401A Ceased KR20200040924A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020197018256A Ceased KR20190077124A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
KR1020207010401A Ceased KR20200040924A (ko) 2011-10-21 2012-10-22 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자

Country Status (14)

Country Link
US (1) US9675708B2 (enExample)
EP (2) EP3400956A1 (enExample)
JP (3) JP2014532628A (enExample)
KR (3) KR20150001711A (enExample)
CN (2) CN104094119A (enExample)
AU (3) AU2012325723A1 (enExample)
BR (1) BR112014009753B1 (enExample)
CA (2) CA2853128C (enExample)
HK (1) HK1201089A1 (enExample)
IN (1) IN2014DN03224A (enExample)
MX (3) MX2014004778A (enExample)
RU (2) RU2014120465A (enExample)
SG (2) SG10201601746TA (enExample)
WO (1) WO2013059831A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220024866A (ko) * 2019-06-21 2022-03-03 강마-헬스코드 (상하이) 바이오테크 컴퍼니 리미티드 생체자기 마이크로스피어와 그 제조 방법 및 사용 방법

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012325723A1 (en) * 2011-10-21 2014-05-15 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules
DK2961378T3 (da) 2013-03-01 2019-11-25 Stealth Biotherapeutics Corp Fremgangsmåder til behandlingen af mitochondrisk sygdom
EP3626252A1 (en) * 2013-03-01 2020-03-25 Stealth Biotherapeutics Corp Methods and compositions for the prevention or treatment of barth syndrome
CA2916977A1 (en) 2013-06-26 2014-12-31 Stealth Biotherapeutics Corp Methods and compositions for detecting and diagnosing diseases and conditions
US10100332B2 (en) 2013-08-23 2018-10-16 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
US11306326B2 (en) 2013-08-23 2022-04-19 Rutgers, The State University Of New Jersey Biologically active synthetic nanoparticle constructs and methods of use thereof
EP3105318A1 (en) * 2014-02-10 2016-12-21 Nvigen, Inc. Cell modulation nanocomposition, and methods of use
CN105440112A (zh) * 2015-12-07 2016-03-30 国家纳米科学中心 多肽-白蛋白偶联药物、其制备方法及应用
EP3463316A4 (en) * 2016-06-03 2020-05-27 Stemgenics, Inc. FUNCTIONALIZED NANOPARTICLES FOR INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS OF MAKING AND USING THE SAME
WO2017210638A1 (en) * 2016-06-03 2017-12-07 Stemgenics, Inc. Direct reprogramming of a human somatic cell to a selected (predetermined) differentiated cell with functionalized nanoparticles
CA3039924A1 (en) * 2016-10-11 2018-04-19 Stemgenics, Inc. Nanoparticles functionalized with gene editing tools and related methods
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
IL299915A (en) * 2017-01-04 2023-03-01 Nanotics Llc Methods for assembling cleaning particles
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2018226529A1 (en) * 2017-06-05 2018-12-13 The Regents Of The University Of Michigan Complexes for delivery of antigenic peptides
WO2019099685A1 (en) 2017-11-15 2019-05-23 Rutgers, The State University Of New Jersey Biodegradable hybrid inorganic nanoscaffolding materials and methods of use and manufacture thereof
CN108287235B (zh) * 2018-02-07 2021-03-09 常州天地人和生物科技有限公司 一种高效、稳定的磁性免疫微球的制备和应用
US20200326325A1 (en) 2019-04-12 2020-10-15 Lisa Diamond Nanosensor chip with compound nanopores
CN110642876A (zh) * 2019-10-10 2020-01-03 南京市口腔医院 半胱氨酸修饰金纳米颗粒和制备方法、应用及促进骨组织再生产品
CN112472685B (zh) * 2020-12-10 2023-03-24 哈尔滨工业大学 一种杂化中性粒细胞机器人的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001019405A2 (de) * 1999-09-14 2001-03-22 Biomedical Apherese Systeme Gmbh Magnetische nanoteilchen mit biochemischer wirksamkeit und verfahren zu ihrer herstellung sowie ihre verwendung
US7329638B2 (en) * 2003-04-30 2008-02-12 The Regents Of The University Of Michigan Drug delivery compositions
JP4901471B2 (ja) * 2004-02-19 2012-03-21 国立大学法人京都大学 体細胞核初期化物質のスクリーニング方法
WO2007149062A2 (en) * 2005-03-14 2007-12-27 Board Of Regents, The University Of Texas System Bioactive fus1 peptides and nanoprticle-polypeptide complexes
CN101389314A (zh) * 2005-03-14 2009-03-18 得克萨斯大学体系董事会 生物活性fus1肽和纳米颗粒-多肽复合物
CN102016814B (zh) * 2005-06-17 2013-10-23 北卡罗来纳大学查珀尔希尔分校 纳米粒子制备方法、系统及材料
US20080213377A1 (en) * 2006-12-08 2008-09-04 Bhatia Sangeeta N Delivery of Nanoparticles and/or Agents to Cells
CA2672998C (en) 2007-01-02 2013-08-06 University Of Central Florida Research Foundation, Inc. Methods and materials for stimulating proliferation of stem cells
KR100925689B1 (ko) 2007-07-25 2009-11-10 한국생명공학연구원 항체와 나노입자를 세포 내로 동시에 전달할 수 있는다기능성 단백질
US8283344B2 (en) 2007-09-10 2012-10-09 Merck & Co., Inc. Method of treating inherited severe neutropenia
KR100951719B1 (ko) * 2007-10-02 2010-04-07 재단법인서울대학교산학협력재단 세포투과성 펩타이드와 형광표지 자성나노입자의 복합체 및그 용도
EP2227241A1 (en) 2007-11-30 2010-09-15 Cytomatrix PTY LTD Methods of inducing pluripotency involving sox2 protein
CN102016058A (zh) * 2008-02-21 2011-04-13 伯纳姆医学研究所 与具有c端元件的肽和蛋白相关的方法和组合物
CN102272142A (zh) * 2008-12-23 2011-12-07 帷幄生物技术公司 非遗传修饰性重编程细胞的组合物和方法
ES2539327T3 (es) * 2009-04-07 2015-06-29 Dow Agrosciences Llc Reparto mediado de nanopartículas de nucleasas específicas de secuencias
AU2012325723A1 (en) * 2011-10-21 2014-05-15 Stemgenics, Inc Functionalized nanoparticles for intracellular delivery of biologically active molecules

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220024866A (ko) * 2019-06-21 2022-03-03 강마-헬스코드 (상하이) 바이오테크 컴퍼니 리미티드 생체자기 마이크로스피어와 그 제조 방법 및 사용 방법

Also Published As

Publication number Publication date
EP2769217A4 (en) 2015-06-03
MX2014004778A (es) 2014-10-17
CN106822868A (zh) 2017-06-13
WO2013059831A1 (en) 2013-04-25
MX2018010696A (es) 2020-09-02
US9675708B2 (en) 2017-06-13
JP2018184485A (ja) 2018-11-22
HK1201089A1 (en) 2015-08-21
MX367656B (es) 2019-08-29
AU2020223737A1 (en) 2020-09-17
CA2938661A1 (en) 2013-04-25
CN104094119A (zh) 2014-10-08
AU2018203848A1 (en) 2018-06-21
BR112014009753A2 (pt) 2017-04-25
JP2014532628A (ja) 2014-12-08
CA2853128A1 (en) 2013-04-25
AU2012325723A1 (en) 2014-05-15
SG11201401658SA (en) 2014-07-30
KR20200040924A (ko) 2020-04-20
RU2014120465A (ru) 2015-11-27
EP2769217A1 (en) 2014-08-27
SG10201601746TA (en) 2016-04-28
JP6560302B2 (ja) 2019-08-14
US20140342004A1 (en) 2014-11-20
JP2017165781A (ja) 2017-09-21
IN2014DN03224A (enExample) 2015-05-22
BR112014009753B1 (pt) 2020-09-15
KR20190077124A (ko) 2019-07-02
EP3400956A1 (en) 2018-11-14
RU2018135567A (ru) 2018-11-15
CA2853128C (en) 2016-09-27

Similar Documents

Publication Publication Date Title
KR20150001711A (ko) 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
US10179194B2 (en) Self-assembling peptides, peptidomimetics and peptidic conjugates as building blocks for biofabrication and printing
EP3395327B1 (en) Non-covalently assembled conductive hydrogel
JP2020519605A (ja) 組織エンジニアリングおよびバイオプリンティングにおける使用のためのゲルを形成し得るペプチド
Ferreira Nanoparticles as tools to study and control stem cells
CN106414477A (zh) 自组装为纳米纤维水凝胶的新超短疏水性肽及其用途
Xu et al. Delivery of plasmid IGF‐1 to chondrocytes via cationized gelatin nanoparticles
CN119040255B (zh) 基于动态水凝胶的外泌体的制备方法及递送体系
HK1236412A (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
HK1236412A1 (en) Functionalized nanoparticles for intracellular delivery of biologically active molecules
KR20190028665A (ko) 기능화된 나노입자(functionalized nanoparticles)를 사용하여 선택된(예정된) 분화된 세포에 대한 사람 체세포의 직접적인 재프로그래밍
EP3638313B1 (en) Non-covalently assembled biomatrix layer
CN119039458B (zh) 兼具靶向和渗透作用的多功能融合肽及其应用
US20170296672A1 (en) Non-ionic and thermoresponsive diblock copolypeptide hydrogels for delivery of molecules and cells
HK40078277A (en) Direct reprogramming of a human somatic cell to a selected (predetermined) differentiated cell with functionalized nanoparticles

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140421

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20161116

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20180416

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20190322

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20180416

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20190624